23andWe

Regeneron purchases 23andMe's assets, marking its third acquisition in the last 18 months.

While Regeneron's acquisition strategy has historically lagged it's peers, the company has more than doubled its all-time acquisition count in the last 18 months. The most recent, $256M deal includes 23andMe's Personal Genome Service, Total Health, and Research Services business lines.

The acquisition matches Regeneron's strategic initiative around genetic testing and genomic research. CB Insights' business relationship data show that the company has been conducting large-scale exome sequencing projects, establishing biobanks, and partnering with health systems to link genetic data with health records for drug discovery and development including key relationships with UK Biobank, Geisinger Health System, UCLA Health, and the Colorado Center for Personalized Medicine.

For Regeneron, 23andMe's genetic data on 15 million individuals will serve as an incredible asset for genomic insights at scale and should help accelerate the paths and timelines for drug discovery.